137 related articles for article (PubMed ID: 38901675)
1. Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
Toniutto P; Falleti E; Cmet S; Cussigh A; Degasperi E; Anolli MP; Sambarino D; Facchetti F; Borghi M; Perbellini R; Monico S; Lampertico P
J Hepatol; 2024 Jun; ():. PubMed ID: 38901675
[TBL] [Abstract][Full Text] [Related]
2. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
J Hepatol; 2024 May; ():. PubMed ID: 38734383
[TBL] [Abstract][Full Text] [Related]
3. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
J Hepatol; 2023 Sep; 79(3):657-665. PubMed ID: 37120031
[TBL] [Abstract][Full Text] [Related]
4. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
5. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
6. Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
Deterding K; Xu C; Port K; Dietz-Fricke C; Xun J; Maasoumy B; Cornberg M; Wedemeyer H
J Viral Hepat; 2023 Jul; 30(7):597-606. PubMed ID: 36924318
[TBL] [Abstract][Full Text] [Related]
7. Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
Mateo R; Xu S; Shornikov A; Yazdi T; Liu Y; May L; Han B; Han D; Martin R; Manhas S; Richards C; Marceau C; Aeschbacher T; Chang S; Manuilov D; Hollnberger J; Urban S; Asselah T; Abdurakhmanov D; Lampertico P; Maiorova E; Mo H
JHEP Rep; 2023 Nov; 5(11):100893. PubMed ID: 37929228
[TBL] [Abstract][Full Text] [Related]
8. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
9. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
[TBL] [Abstract][Full Text] [Related]
10. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
11. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods.
Anolli MP; Renteria SU; Degasperi E; Borghi M; Facchetti F; Sambarino D; Perbellini R; Monico S; Ceriotti F; Lampertico P
Liver Int; 2024 Mar; 44(3):831-837. PubMed ID: 38247385
[TBL] [Abstract][Full Text] [Related]
12. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; Scholtes C; Holzmann H; van Bömmel F; Borghi M; Perbellini R; Rimondi A; Farina E; Trombetta E; Manunta M; Porretti L; Prati D; Ceriotti F; Zoulim F; Bertoletti A; Lampertico P
J Hepatol; 2022 Feb; 76(2):464-469. PubMed ID: 34699951
[TBL] [Abstract][Full Text] [Related]
14. Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L; Cotler SJ; Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Facchetti F; Ceriotti F; Lampertico P; Dahari H
JHEP Rep; 2024 Feb; 6(2):100966. PubMed ID: 38274491
[TBL] [Abstract][Full Text] [Related]
15. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
16. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
17. Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.
Liu H; Zakrzewicz D; Nosol K; Irobalieva RN; Mukherjee S; Bang-Sørensen R; Goldmann N; Kunz S; Rossi L; Kossiakoff AA; Urban S; Glebe D; Geyer J; Locher KP
Nat Commun; 2024 Mar; 15(1):2476. PubMed ID: 38509088
[TBL] [Abstract][Full Text] [Related]
18. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression.
Jachs M; Panzer M; Hartl L; Schwarz M; Balcar L; Camp JV; Munda P; Mandorfer M; Trauner M; Aberle SW; Zoller H; Reiberger T; Ferenci P
JHEP Rep; 2023 Aug; 5(8):100751. PubMed ID: 37360907
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update.
Ferenci P; Reiberger T; Jachs M
Cells; 2022 Nov; 11(22):. PubMed ID: 36428959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
